167215-79-4

Upstream product

• 152863-83-7 N-[2-[(triphenylmethyl)thio]ethyl]-2-[[2-[(triphenylmethyl)thio]ethyl]amino]acetamide 
• 160446-22-0 methyl 4-(methanesulphonylmethyl)benzoate 
• 6908-41-4 4-(methoxycarbonyl)benzyl alcohol 
• 167215-77-2 methyl 4-(((methylsulfonyl)oxy)methyl)benzoate 
• 167215-78-3 N-[4-(carbomethoxy)benzyl]-N,N'-bis[(2-triphenylmethylthio)ethyl]glycinamide 

Downstream Products

• 167215-80-7 N-[4-(Carboxy)benzyl]-N,N'-bis[(2-triphenylmethyl-thio)ethyl]glycinamide N-hydroxysuccinimide ester 

Relevant academic research and scientific papers

Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation

The present invention provides novel diagnostic compositions comprising a radiolabeled LTB4 binding agent and a radiolabeled perfusion imaging agent, diagnostic kits comprising such compositions, and methods of concurrent imaging in a mammal comprising ad

Radiopharmaceuticals for imaging infection and inflammation

The present invention provides novel radiopharmaceuticals useful for the diagnosis of infection and inflammation, reagents and kits useful for preparing the radiopharmaceuticals, methods of imaging sites of infection and/or inflammation in a patient, and

LTB4 antagonists and radiopharmaceuticals for imaging infection and inflammation

The present invention provides novel radiopharmaceutials useful for the diagnosis of infection and inflammation, reagents and kits useful for preparing the radiopharmaceuticals, methods of imaging sites of infection and/or inflammation in a patient, and methods of diagnosing diseases associated with infection or inflammation in patients in need of such diagnosis. The radiopharmaceuticals bind in vivo to the leukotriene B4 (LTB4) receptor on the surface of leukocytes which accumulate at the site of infection and inflammation. The reagents provided by this invention are also useful for the treatment of diseases associated with infection and inflammation.

Radiopharmaceuticals for imaging infection and inflammation

The present invention provides novel radiopharmaceuticals useful for the diagnosis of infection and inflammation, reagents and kits useful for preparing the radiopharmaceuticals, methods of imaging sites of infection and/or inflammation in a patient, and

Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders

This invention provides novel radiopharmaceuticals that are radiolabeled cyclic compounds containing carbocyclic or heterocyclic ring systems which act as antagonists of the platelet glycoprotein IIb/IIIa complex; to methods of using said radiopharmaceuticals as imaging agents for the diagnosis of arterial and venous thrombi; to novel reagents for the preparation of said radiopharmaceuticals; and to kits comprising said reagents.

Tc-99m-labeled fibrinogen receptor antagonists: Design and synthesis of cyclic RGD peptides for the detection of thrombi

Tc-99m labeled derivatives of N-Me-Arg-Gly-Asp containing cyclic peptide GP IIb/IIIa receptor antagonists are potential radiopharmaceuticals for the diagnosis of thrombosis. The design and synthesis of these peptides are described. These compounds are incorporated in rapidly growing thrombi under both arterial and venous conditions in canine models. Thrombi are clearly visible in images acquired at 50 min.